These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 9330999

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker.
    Sever P.
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S91-5. PubMed ID: 9331018
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Candesartan cilexetil: an update of its use in essential hypertension.
    Easthope SE, Jarvis B.
    Drugs; 2002 Sep; 62(8):1253-87. PubMed ID: 12010090
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A new class of diacidic nonpeptide angiotensin II receptor antagonists: candesartan cilexetil.
    Naka T, Kubo K, Inada Y, Nishikawa K.
    Drug Des Discov; 1999 Aug; 16(2):95-108. PubMed ID: 10533806
    [Abstract] [Full Text] [Related]

  • 11. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect.
    Elmfeldt D, George M, Hübner R, Olofsson B.
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S49-53. PubMed ID: 9331007
    [Abstract] [Full Text] [Related]

  • 12. Pharmacologic properties of candesartan cilexetil--possible mechanisms of long-acting antihypertensive action.
    Inada Y, Ojima M, Kanagawa R, Misumi Y, Nishikawa K, Naka T.
    J Hum Hypertens; 1999 Jan; 13 Suppl 1():S75-80. PubMed ID: 10076925
    [Abstract] [Full Text] [Related]

  • 13. Candesartan: a new-generation angiotensin II AT1 receptor blocker: pharmacology, antihypertensive efficacy, renal function, and renoprotection.
    Morsing P.
    J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S248-54. PubMed ID: 9892173
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Candesartan cilexetil. A review of its use in essential hypertension.
    McClellan KJ, Goa KL.
    Drugs; 1998 Nov; 56(5):847-69. PubMed ID: 9829158
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairment.
    de Zeeuw D, Remuzzi G, Kirch W.
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S37-42. PubMed ID: 9331004
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetic drug interaction studies with candesartan cilexetil.
    Jonkman JH, van Lier JJ, van Heiningen PN, Lins R, Sennewald R, Högemann A.
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S31-5. PubMed ID: 9331003
    [Abstract] [Full Text] [Related]

  • 18. Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients.
    Fridman K, Andersson OK, Wysocki M, Friberg P, Sunzel M.
    Eur J Clin Pharmacol; 1998 Sep; 54(7):497-501. PubMed ID: 9832289
    [Abstract] [Full Text] [Related]

  • 19. Preserving target-organ function with candesartan cilexetil in patients with hypertension.
    Zannad F.
    Blood Press Suppl; 2000 Sep; 1():36-9. PubMed ID: 11059635
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetic-pharmacodynamic interactions of candesartan cilexetil and losartan.
    Azizi M, Chatellier G, Guyene TT, Ménard J.
    J Hypertens; 1999 Apr; 17(4):561-8. PubMed ID: 10404959
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.